GlaxoSmithKline Consumer Healthcare Limited announces results for the first quarter ended June 30, 2018

GlaxoSmithKline Consumer Healthcare Limited announces results for the first quarter ended June 30, 2018

 Comparable* Revenue growth of 16.4%, PBT growth of 52%

Gurugram, 7 August 2018: GlaxoSmithKline Consumer Healthcare Limited today declared its financial results for the first quarter ended June 30, 2018. The comparable* Revenue for the company recorded a growth of 16.4%. The quarter reported revenue of Rs. 1107 crore, while the PBT was at Rs. 312 crores, a growth of 52%. The quarter also witnessed an increase in volume growth at 12.8%. 

Commenting on the results, Navneet Saluja, Managing Director, GlaxoSmithKline Consumer Healthcare Limited said, “We witnessed a positive growth in the first quarter on the back of strong performance of Horlicks and Boost. Our consumer campaigns have been well accepted and they have provided suitable growth momentum. All the channels including rural have performed well and our direct rural foothold now reaches over 22,000 villages.

Investments behind fast growing segments of high science, such as Protein +, Growth +, and new formats like Boost Ready-to-drink, are showing good uptakes. Our access agenda continues to gain in strength and today our various SKU’s reach out to over 1.78 MN outlets.

With strong business fundamentals, high-science based products and committed team, we are well poised to deliver a healthy year.” added Saluja.

 Performance Highlights:

  • Health food drink portfolio continues to be the market leader with 54% value share**
  • Strong performance by Horlicks and Boost that witnessed 18% growth
  • Boost continue to maintain its strong growth momentum with double digit volume growth.
  • Boost forayed into an all new Ready to Drink (RTD) format in Tamil Nadu.

*Comparable: Reflecting the accounting impact of GST (Excise and other tax costs under earlier regime, now subsumed under GST and netted from Turnover in base)

**Source: Nielsen, June’18

About GlaxoSmithKline Consumer Healthcare Ltd

GSK Consumer Healthcare Ltd is the category leader in Indian health food drinks industry. Our flagship product Horlicks leads the market, while Boost is among the top three health food drink brands that India prefers. Our manufacturing plants are located in Nabha, Rajahmundry and Sonepat. In India we have an engaged workforce of over 3800 employees. GSK also markets and distributes a range of everyday health products such as Eno, Crocin, Iodex and Sensodyne. Our marketing and distribution network comprises over 800 distributors and a direct coverage of over 8 lakh retail outlets.

GSK Consumer Healthcare Ltd is an associate of GlaxoSmithKline plc. of U.K, one of world’s largest consumer healthcare companies. We have a heritage that goes back over 160 years. Our purpose is to help more people around the world to do more, feel better and live longer with everyday healthcare products.  Our goal is to build a global, growing business - we call a Fast-Moving Consumer Healthcare (FMCH) company - dedicated to everyday healthcare with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects.

GSK Consumer Healthcare globally owns some of the world’s best loved healthcare brands, successful in over 100 countries. These include Sensodyne, Theraflu, Paradontax, Panadol, Polident, Otrivin, Horlicks and Physiogel

Media Contacts

Genesis Burson-Marsteller

Rikhil Seth: /+91 9811818270

M Sindhu: /+91 9899428304

GlaxoSmithKline Consumer Healthcare

Deepa Dey:

Kinshuk Gupta: